Hyleukin was successfully created by fusing engineered IL-7 to hyFc:

1) Engineering IL-7 leads to high production rate in mammalian cell culture system.

2) Application of hyFc technology optimizes the function of IL-7 by increasing half-life and by preventing death of target cells bearing IL-7 receptors.

3) The hyFc fusion to IL-7 ​​increases systemic T cell immunity via subcutaneous injection and also ​​activate​s​ T cell immunity in mucosal site through transcytosis.​